Media hub

Chiesi appoints David Khougazian as Group Chief Executive Officer to lead the next phase of innovation-driven growth

Chiesi Group delivers solid H1 2026 performance, combining growth, continued investment in innovation and positive economic impact across communities

Chiesi advances its Carbon Minimal Inhaler journey as European submissions for its Single Inhaler Triple Therapy (SITT) and ICS/LABA combination next-generation propellant pMDIs are validated

Chiesi Group Chair Signs Open Letter Calling for Stronger Support for Pharmaceutical Innovation in Europe

Chiesi announces a partnership with Abdi İbrahim in Türkiye

Chiesi Returns Seralutinib Rights to Gossamer Bio as Companies Terminate Collaboration and License Agreement